What is NewAmsterdam Pharma Company's deferred revenue?

NewAmsterdam Pharma Company (NAMS) reported deferred revenue of -$3.03M in Q2 2025.

How has NewAmsterdam Pharma Company's deferred revenue changed year-over-year?

NewAmsterdam Pharma Company's deferred revenue decreased by 33.0% year-over-year, from -$2.28M to -$3.03M.

NewAmsterdam Pharma Company NAMS Deferred Revenue

Deferred Revenue at other companies

UnitedHealth GroupUNH

$20M+300%

Electronic ArtsEA

$133.25M+568%

Target HospitalityTH

$11.18M+3,495%

AirbnbABNB

$988M-10.6%

CalixCALX

$232K-92.7%

AbCellera Biologics Inc.ABCL

-$8.03M-160%

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed August 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's deferred revenue?: NewAmsterdam Pharma Company (NAMS) reported deferred revenue of -$3.03M in Q2 2025.
How has NewAmsterdam Pharma Company's deferred revenue changed year-over-year?: NewAmsterdam Pharma Company's deferred revenue decreased by 33.0% year-over-year, from -$2.28M to -$3.03M.